You are here

Scalable Generation of iPSC-MSCs

Human mesenchymal stem cell (MSC) therapy represents a potentially exciting treatment choice for disorders resulting from an inflammatory/heightened immune response. In a new STEM CELLS Translational Medicine study from the labs of Carl A. Gregory and Roland Kaunas (Texas A&M Health Science Center, Bryan, TX, USA), researchers report on their studies regarding the therapeutic development of induced pluripotent stem cell-derived MSCs (iPSC-MSCs) Rogers et al. established procedures for the manufacture of iPSC-MSCs attached to novel digestible microcarriers in scalable bioreactors that permitted rapid harvest at high yields and viability. Overall, this study represents the first description of a robust, scalable, and cost-effective method for generating human iPSC-MSCs, which represents a significant contribution to their translational potential. Image - Osteogenic and adipogenic differentiation potential after RWVB expansion on GelMA microcarriers.